Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (ROCKI Study)

NCT02668640 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02668640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02668640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (ROCKI Study)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
May 1, 2016
Completion date
August 13, 2018
Enrollment
55 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis